Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorder and is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand and some parts of Europe, and is also available in the USA as an orphan drug.
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorder. Tetrabenazine is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand. Tetrabenazine is marketed under the trade names Nitoman in Canada and Xenazine in some parts of Europe. Tetrabenazine is also available in the USA as an orphan drug.